Puma Biotechnology | PBYI - Ingresos Por Ventas





Ventas Cambio Fecha
Agios Pharmaceuticals USD 19.97M 7.07M 2025-12
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
Amgen USD 9.9B 340M 2025-12
Biogen USD 2.28B 250M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Daiichi Sankyo JPY 558.11B 57.35B 2025-12
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Exelixis USD 598.66M 860K 2025-12
Gilead Sciences USD 7.93B 130M 2025-12
Glaxosmithkline GBP 11.46B 59.16M 2025-12
Incyte USD 1.51B 140M 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
Moderna USD 678M 342M 2025-12
Novartis USD 13.86B 50M 2025-12
Pfizer USD 17.58B 880M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sangamo BioSciences USD 356K 125K 2024-06
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Takeda JPY 1.19T 80B 2025-12
TG Therapeutics USD 192.57M 30.87M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12